Adverum Biotechnologies Inc logo

ADVM - Adverum Biotechnologies Inc Share Price

$17.77 -0.4  -2.4%

Last Trade - 8:16pm

Mid Cap
Market Cap £1.11bn
Enterprise Value £888.0m
Revenue £191k
Position in Universe 2031st / 6368
Unlock ADVM Revenue
Relative Strength (%)
1m -15.4%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -32.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.57 2.32 1.46 1.85 1.61 0.25 0.30 0.32 -15.3%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Adverum Biotechnologies Inc revenues was not reported. Net loss increased 58% to $22.9M. Higher net loss reflects Research and development -gross increase of 42% to $13.5M (expense), General and administrative - Balancing v increase of 55% to $6.9M (expense), Stock-based Compensation in SGA increase of 91% to $2.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ADVM
Graphical History


ADVM Revenue Unlock ADVM Revenue

Net Income

ADVM Net Income Unlock ADVM Revenue

Normalised EPS

ADVM Normalised EPS Unlock ADVM Revenue

PE Ratio Range

ADVM PE Ratio Range Unlock ADVM Revenue

Dividend Yield Range

ADVM Dividend Yield Range Unlock ADVM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ADVM EPS Forecasts Unlock ADVM Revenue
Profile Summary

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products (AVA-311) for ophthalmic diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its capabilities include clinical development, vector discovery, and in-house manufacturing, specifically in process development, assay development and current Good Manufacturing Practices (cGMP) quality control.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated July 17, 2006
Public Since July 31, 2014
No. of Shareholders: 15
No. of Employees: 114
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 80,295,560
Free Float (0.0%)
Eligible for
ADVM Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ADVM
Upcoming Events for ADVM
Thursday 6th August, 2020 Estimate
Q2 2020 Adverum Biotechnologies Inc Earnings Release
Monday 10th August, 2020
Q2 2020 Adverum Biotechnologies Inc Earnings Call
Thursday 5th November, 2020 Estimate
Q3 2020 Adverum Biotechnologies Inc Earnings Release
Frequently Asked Questions for Adverum Biotechnologies Inc
What is the Adverum Biotechnologies Inc share price?

As of 8:16pm, shares in Adverum Biotechnologies Inc are trading at $17.77, giving the company a market capitalisation of £1.11bn. This share price information is delayed by 15 minutes.

How has the Adverum Biotechnologies Inc share price performed this year?

Shares in Adverum Biotechnologies Inc are currently trading at $17.77 and the price has moved by 51.67% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Adverum Biotechnologies Inc price has moved by 32.29% over the past year.

What are the analyst and broker recommendations for Adverum Biotechnologies Inc?

Of the analysts with advisory recommendations for Adverum Biotechnologies Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Adverum Biotechnologies Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Adverum Biotechnologies Inc next release its financial results?

Adverum Biotechnologies Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Adverum Biotechnologies Inc dividend yield?

Adverum Biotechnologies Inc does not currently pay a dividend.

Does Adverum Biotechnologies Inc pay a dividend?

Adverum Biotechnologies Inc does not currently pay a dividend.

When does Adverum Biotechnologies Inc next pay dividends?

Adverum Biotechnologies Inc does not currently pay a dividend.

How do I buy Adverum Biotechnologies Inc shares?

To buy shares in Adverum Biotechnologies Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Adverum Biotechnologies Inc?

Shares in Adverum Biotechnologies Inc are currently trading at $17.77, giving the company a market capitalisation of £1.11bn.

Where are Adverum Biotechnologies Inc shares listed? Where are Adverum Biotechnologies Inc shares listed?

Here are the trading details for Adverum Biotechnologies Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: ADVM
What kind of share is Adverum Biotechnologies Inc?

Based on an overall assessment of its quality, value and momentum, Adverum Biotechnologies Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Adverum Biotechnologies Inc share price forecast 2020?

Shares in Adverum Biotechnologies Inc are currently priced at $17.77. At that level they are trading at 41.48% discount to the analyst consensus target price of 0.00.

Analysts covering Adverum Biotechnologies Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.178 for the next financial year.

How can I tell whether the Adverum Biotechnologies Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adverum Biotechnologies Inc. Over the past six months, the relative strength of its shares against the market has been 80.18%. At the current price of $17.77, shares in Adverum Biotechnologies Inc are trading at 30.84% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Adverum Biotechnologies Inc PE Ratio?

We were not able to find PE ratio data for Adverum Biotechnologies Inc.

Who are the key directors of Adverum Biotechnologies Inc?

Adverum Biotechnologies Inc's management team is headed by:

Mehdi Gasmi - DRC
Leone Patterson - PRE
Patrick Machado - CHM
Eric Carter - IND
Aaron Osborne - OTH
Thomas Leung - CFO
Rekha Hemrajani - IND
James Scopa - IND
Mark Lupher - IND
Peter Soparkar - OTH
Angela Thedinga - CTO
Laurent Fischer - CEO
Heikki Jouttijarvi - VPR
Thomas Kochy - VPR
Who are the major shareholders of Adverum Biotechnologies Inc?

Here are the top five shareholders of Adverum Biotechnologies Inc based on the size of their shareholding:

RA Capital Management, LP Hedge Fund
Percentage owned: 9.06% (7.27m shares)
Avoro Capital Advisors LLC Investment Advisor/Hedge Fund
Percentage owned: 8.9% (7.15m shares)
Versant Ventures Venture Capital
Percentage owned: 8.72% (7.00m shares)
RTW Investments L.P. Investment Advisor/Hedge Fund
Percentage owned: 8.26% (6.63m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.72% (4.59m shares)
Similar to ADVM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.